Business & Finance

Nventa Biopharmaceuticals announces third quarter 2006 financial results

Published in Cancer Weekly, December 12th, 2006

Nventa Biopharmaceuticals Corporation (NVN) announced financial results for the third quarter, reporting continuing operations of $2.3 million or $0.03 (US$0.03) per share, for the three months, compared to a net loss from continuing operations of $5.7 million, or $0.08 (US$0.07) per share, for the same period in 2005. All amounts, unless specified otherwise, are in Canadian dollars.

For the nine months, the company reported a net loss from continuing operations of $8.0 million, or $0.10 (US$0.09) per share, compared to a net loss from continuing operations of $23.2 million, or $0.32 (US$0.29) per share, for the same period in 2005. The company had cash and cash...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-12-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry